A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 16 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 26 Mar 2014 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 19 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.